Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabenazine SCHEMBL13401094 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29383441 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992567 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29609598 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992566 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL20049732 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971276 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL12394431 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL62026 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29380971 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20230355514-A1 | PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355514-A1 | PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355514-A1 | PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023172849-A1 | VALBENAZINE, A VMAT2 INHIBITOR, AS A FREE BASE A TOSYLATE OR DITOSYLATE SALT, FOR USE IN THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11666566-B2 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220211678-A1 | USES OF (+)-A-DIHYDROTETRABENAZINE IN METHODS OF TREATING MOVEMENT DISORDER | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| US-20220016107-A1 | PHARMACEUTICAL COMPOSITIONS | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2022-01-20 | — | — | US | disclosed |
| US-20210322308-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20160346200-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS LLC | 2016-12-01 | — | — | US | disclosed |
| WO-2015120110-A2 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2012081031-A1 | PROCESS FOR PREPARING TETRABENAZINE | ENALTEC LABS PVT. LTD. (IN) | 2012-06-21 | — | — | WO | disclosed |
| US-8008500-B2 | Intermediates useful for making tetrabenazine compounds | GENERAL ELECTRIC COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-7897768-B2 | Method for making tetrabenazine compounds | GENERAL ELECTRIC COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | Biovali Laboratories International (Barbados) S.R.L. (BB) | 2010-04-08 | — | — | US | disclosed |
| US-20100055133-A1 | PHARMACEUTICAL COMPOSITIONS | Biovail Laboratories International (Barbados) S.R.L (BB) | 2010-03-04 | — | — | US | disclosed |
| US-20090275605-A1 | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease | CAMBRIDGE LABORATORIES (IRELAND) LIMITED (IE) | 2009-11-05 | — | — | US | disclosed |
| US-20080306269-A1 | INTERMEDIATES USEFUL FOR MAKING TETRABENAZINE COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306267-A1 | METHOD FOR MAKING TETRABENAZINE COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322308-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | MC2R, ADCYAP1R1, PCSK9 | SLC18A2 57/4885KDM4E 4255/4885ABCB11 22/4885 |
| US-20100055133-A1 | PHARMACEUTICAL COMPOSITIONS | HTT, TTR, ATXN10 | SLC18A2 114/4885KDM4E 3727/4885ABCB11 473/4885 |
| US-20080306269-A1 | INTERMEDIATES USEFUL FOR MAKING TETRABENAZINE COMPOUNDS | TBC1D15, ADH1C, TBC1D5 | SLC18A2 2723/4885KDM4E 3472/4885ABCB11 4702/4885 |
| US-20220016107-A1 | PHARMACEUTICAL COMPOSITIONS | SLC18A2, SUCNR1, SLC16A1 | SLC18A2 1/4885KDM4E 2534/4885ABCB11 1534/4885 |
| US-20230355514-A1 | PHARMACEUTICAL FORMULATIONS | MC2R, ADCYAP1R1, PCSK9 | SLC18A2 71/4885KDM4E 4290/4885ABCB11 6/4885 |
| US-20090275605-A1 | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease | IL17A, HSD17B13, HSD11B1 | SLC18A2 3737/4885KDM4E 3746/4885ABCB11 345/4885 |
| US-11666566-B2 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | SLC18A2, SLC6A2, SLC18A1 | SLC18A2 1/4885KDM4E 1999/4885ABCB11 127/4885 |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | HTR1D, HTR5A, PCNP | SLC18A2 180/4885KDM4E 1239/4885ABCB11 1426/4885 |
| US-20160346200-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | SI, CFTR, SUCNR1 | SLC18A2 100/4885KDM4E 3211/4885ABCB11 12/4885 |
| US-20080306267-A1 | METHOD FOR MAKING TETRABENAZINE COMPOUNDS | ADH1C, TBC1D15, TBC1D5 | SLC18A2 2629/4885KDM4E 3552/4885ABCB11 4710/4885 |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | FLNB, SETD1B, HTR5A | SLC18A2 23/4885KDM4E 515/4885ABCB11 962/4885 |
| US-20220211678-A1 | USES OF (+)-A-DIHYDROTETRABENAZINE IN METHODS OF TREATING MOVEMENT DISORDER | HTT, COMT, QDPR | SLC18A2 29/4885KDM4E 3311/4885ABCB11 3393/4885 |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | UGT2B7, CYP3A7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC18A2 471/4885KDM4E 1817/4885ABCB11 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.